Outcome | Illustrative comparative effecta (95% CI) | No. of participants | Quality of the evidence (GRADE) | |
---|---|---|---|---|
Assumed effect (control) | Corresponding effect | |||
mLCDb | ||||
Systolic blood pressure, mm Hg (follow-up: 8–24 weeks) | −4.55 | −3.25 (−7.28 to 0.77) | 195 (2 studies) | ⊕⊝⊝⊝ Very Low |
Diastolic blood pressure, mm Hg (follow-up: 8–24 weeks) | −4.00 | −1.80 (− 4.56 to 0.96) | 93 (1 study) | ⊕⊝⊝⊝ Very Low |
Triglyceride, mg/dL (follow-up: 8–24 weeks) | −15.48 | −35.58 (−52.84 to − 18.33) | 195 (2 studies) | ⊕⊝⊝⊝ Very Low |
LDL-C, mg/dL (follow-up: 8–24 weeks) | −0.30 | 0.00 (−9.55 to 9.55) | 93 (1 study) | ⊕⊝⊝⊝ Very Low |
HDL-C, mg/dL (follow-up: 36–52 weeks) | 2.3 | 1.60 (−1.13 to 4.33) | 93 (1 study) | ⊕⊝⊝⊝ Very Low |
Body weight, kg (follow-up: 8–24 weeks) | −6.2 | −1.81 (−3.93 to 0.30) | 195 (2 studies) | ⊕⊝⊝⊝ Very Low |
FMD, % (follow-up: 36–52 weeks) | −0.6 | 0.30 (− 0.58 to 1.18) | 93 (1 study) | ⊕⊝⊝⊝ Very Low |
VLCDc | ||||
Systolic blood pressure, mm Hg (follow-up: 8–24 weeks) | −6.3 | −1.34 (−5.20 to 2.51) | 232 (2 studies) | ⊕⊝⊝⊝ Very Low |
Diastolic blood pressure, mm Hg (follow-up: 8–24 weeks) | −4.0 | 2.01 (−0.61 to 4.63) | 232 (2 studies) | ⊕⊝⊝⊝ Very Low |
Triglyceride, mg/dL (follow-up: 8–24 weeks) | −19.95 | −10.17 (−43.00 to 22.67) | 232 (2 studies) | ⊕⊝⊝⊝ Very Low |
LDL-C, mg/dL (follow-up: 8–24 weeks) | −6.75 | 8.91 (−9.27 to 27.08) | 232 (2 studies) | ⊕⊝⊝⊝ Very Low |
HDL-C, mg/dL (follow-up: 8–24 weeks) | 2.75 | 1.85 (−5.98 to 9.69) | 232 (2 studies) | ⊕⊝⊝⊝ Very Low |
Body weight, kg (follow-up: 8–24 weeks) | −6.05 | −1.16 (−2.65 to 0.34) | 232 (2 studies) | ⊕⊝⊝⊝ Very Low |
FMD, % (follow-up: 36–52 weeks) | −0.3 | −1.80 (−3.48, − 0.12) | 49 (1 study) | ⊕⊝⊝⊝ Very Low |